Manus Neurodynamica is a technology company.
Manus Neurodynamica has raised $6.8M across 4 funding rounds.
Manus Neurodynamica has raised $6.8M in total across 4 funding rounds.
Manus Neurodynamica is a medtech company developing neuroscience technologies for diagnosing and monitoring neuromotor impairments, primarily through its flagship NeuroMotor Pen—a non-invasive digital pen that analyzes fine motor skills via handwriting and drawing tasks.[1][3][4] The device serves clinicians in primary care, community screening, and specialist settings, targeting patients with conditions like Parkinson's disease, tremors, and other neurological disorders to enable faster diagnosis, streamlined referrals, optimized treatment, and reduced healthcare costs.[1][2][3] With $6.73M raised since 2008, including a $3.2M round two years ago, the company remains in unattributed VC stage and active, focusing on Europe-wide deployment to revolutionize patient pathways.[1][2]
Founded in 2008 in Edinburgh, Scotland, by Rutger van Herpen, who serves as CEO, Manus Neurodynamica emerged from his PhD research in neuroscience applied to clinical tools.[1][4][5] While at a consulting firm, Rutger ideated non-invasive devices leveraging motion analysis; he channeled these into Manus, coordinating the EU-funded DiPAR project for initial NeuroMotor Pen development and validation.[4] His prior experience spans biomedical engineering at J&J Cordis and Philips, plus project management in Dutch healthcare via Cap Gemini, complemented by degrees in bioengineering and business administration.[4] The company evolved from broad neuromotor tech visions to specialized clinical applications like Parkinson's diagnosis and upper limb rehab, with board expertise including Oxford Parkinson's researcher Dr. Alparslan Sahin on biomarkers and sleep-related neurodegeneration.[4]
Manus rides the digital health and medtech wave in neurology, where aging populations drive demand for early Parkinson's detection—estimated at 10M global cases—and scalable tools amid specialist shortages.[1][3] Timing aligns with post-pandemic telehealth shifts and wearable/digital biomarker adoption, fueled by EU funding for patient-centered care re-engineering.[3][4] Market tailwinds include rising neuromotor disease prevalence and cost pressures on healthcare, positioning Manus to influence ecosystems by enabling primary care screening, reducing unnecessary referrals, and supporting pharma trials via precise monitoring.[1][2][3]
Manus Neurodynamica stands poised for expansion with its validated NeuroMotor Pen, likely pursuing regulatory approvals, partnerships, and commercial scaling in Europe amid overdue filings signaling administrative hurdles but ongoing activity.[1][5] Trends like AI-enhanced diagnostics and remote monitoring will amplify its edge, potentially evolving into full neuromotor platforms influencing global standards for accessible neurology care. As digital pens redefine "low-cost wearables," Manus could catalyze earlier interventions, tying back to its core mission of transforming lives through precise, patient-first neuromotor tech.[2][3][4]
Manus Neurodynamica has raised $6.8M in total across 4 funding rounds.
Manus Neurodynamica's investors include Northstar Ventures, Par Equity, Puma Growth Partners, Techstart Ventures.
Manus Neurodynamica has raised $6.8M across 4 funding rounds. Most recently, it raised $3.0M Venture Round in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $3.0M Venture Round | Northstar Ventures, Par Equity, Puma Growth Partners, Techstart Ventures | |
| Jan 1, 2021 | $2.0M Venture Round | Northstar Ventures, Par Equity | |
| Jun 1, 2020 | $950K Venture Round | Par Equity, Techstart Ventures | |
| Oct 1, 2018 | $830K Venture Round | Par Equity, Techstart Ventures |